Recurrent Cystitis in Women—A Real-World Analysis of Bacteria Spectrum and Resistance Situation for Calculated Therapy
Abstract
:1. Introduction
2. Results
3. Discussion
4. Materials and Methods
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Bonkat, G.; Bartoletti, R.; Bruyère, F.; Cai, T.; Geerlings, S.E.; Kranz, J.; Köves, B.; Medina, J.; Pilatz, A.; Schneidewind, L.; et al. EAU Guidelines Urological Infections. 2020. Available online: https://uroweb.org/guideline/urological-infections/ (accessed on 2 December 2020).
- Raz, R.; Stamm, W.E. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N. Engl. J. Med. 1993, 329, 753–756. [Google Scholar] [CrossRef] [PubMed]
- Piechota, H. Rezidivierende und katheterassoziierte Harnwegsinfektionen: Prophylaxe und Prävention (Recurrent and catheter-associated urinary tract infections: Prophylaxis and prevention). Urologe A 2017, 56, 734–745. [Google Scholar] [CrossRef] [PubMed]
- Foxman, B. Epidemiology of urinary tract infections: Incidence, morbidity, and economic costs. Dis. Mon. 2003, 49, 53–70. [Google Scholar] [CrossRef] [PubMed]
- Schollum, J.B.W.; Walker, R.J. Adult urinary tract infection. Br. J. Hosp. Med. 2012, 73, 218–223. [Google Scholar] [CrossRef] [PubMed]
- Ben Hadj Messaoud, S.; Demonchy, E.; Mondain, V. Recurring Cystitis: How Can We Do Our Best to Help Patients Help Themselves? Antibiotics 2022, 11, 269. [Google Scholar] [CrossRef]
- Kahlmeter, G. Prevalence and antimicrobial susceptibility of pathogens in uncomplicated cystitis in Europe: The ECOaSENS study. Int. J. Antimicrob. Agents 2003, 22, 49–52. [Google Scholar] [CrossRef]
- Naber, K.G.; Schito, G.; Botto, H.; Palou, J.; Mazzei, T. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): Implications for empiric therapy. Eur. Urol. 2008, 54, 1164–1175. [Google Scholar] [CrossRef]
- Wagenlehner, F.M.E.; Wagenlehner, C.; Savov, O.; Gualco, L.; Schito, G.; Naber, K.G. Klinik und Epidemiologie der unkomplizierten Zystitis bei Frauen. Deutsche Ergebnisse der ARESC-Studie (Clinical aspects and epidemiology of uncomplicated cystitis in women: German results of the ARESC Study). Urologe A 2010, 49, 253–261. [Google Scholar] [CrossRef]
- Kranz, J.; Schmidt, S.; Lebert, C.; Schneidewind, L.; Vahlensieck, W.; Sester, U.; Fünfstück, R.; Helbig, S.; Hofmann, W.; Hummers, E.; et al. Epidemiologie, Diagnostik, Therapie, Prävention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten: Aktualisierung 2017 der interdisziplinären AWMF S3-Leitlinie (Epidemiology, diagnostics, therapy, prevention and management of uncomplicated bacterial outpatient acquired urinary tract infections in adult patients: Update 2017 of the interdisciplinary AWMF S3 guideline). Urologe A 2017, 56, 746–758. [Google Scholar] [CrossRef]
- Dason, S.; Dason, J.T.; Kapoor, A. Guidelines for the diagnosis and management of recurrent urinary tract infection in women. Can. Urol. Assoc. J. 2011, 5, 316–322. [Google Scholar] [CrossRef]
- Kim, D.S.; Lee, J.W. Urinary Tract Infection and Microbiome. Diagnostics 2023, 13, 1921. [Google Scholar] [CrossRef] [PubMed]
- Park, M.G.; Cho, S.; Oh, M.M. Menopausal Changes in the Microbiome-A Review Focused on the Genitourinary Microbiome. Diagnostics 2023, 13, 1193. [Google Scholar] [CrossRef]
- Cai, T.; Tamanini, I.; Collini, L.; Brugnolli, A.; Migno, S.; Mereu, L.; Tateo, S.; Pilatz, A.; Rizzo, M.; Liguori, G.; et al. Management of Recurrent Cystitis in Women: When Prompt Identification of Risk Factors Might Make a Difference. Eur. Urol. Focus 2022, 8, 1476–1482. [Google Scholar] [CrossRef]
- Kranz, J.; Bartoletti, R.; Bruyère, F.; Cai, T.; Geerlings, S.; Köves, B.; Schubert, S.; Pilatz, A.; Veeratterapillay, R.; Wagenlehner, F.M.; et al. European Association of Urology Guidelines on Urological Infections: Summary of the 2024 Guidelines. Eur. Urol. 2024, 86, 27–41. [Google Scholar] [CrossRef]
- Tyagi, P.; Tyagi, S.; Stewart, L.; Glickman, S. SWOT and Root Cause Analyses of Antimicrobial Resistance to Oral Antimicrobial Treatment of Cystitis. Antibiotics 2024, 13, 328. [Google Scholar] [CrossRef] [PubMed]
- Piraux, A.; Hammoud, R.; Riou, J.; Lebdai, S.; Faure, S. Assessment of the Compliance of Cystitis Management According to French Recommendations through the Analysis of Prescriptions Collected in Community Pharmacies. Antibiotics 2022, 11, 976. [Google Scholar] [CrossRef]
- Llor, C.; Bjerrum, L. Antimicrobial resistance: Risk associated with antibiotic overuse and initiatives to reduce the problem. Ther. Adv. Drug Saf. 2014, 5, 229–241. [Google Scholar] [CrossRef] [PubMed]
- Schneeberger, C.; Geerlings, S.E.; Middleton, P.; Crowther, C.A. Interventions for preventing recurrent urinary tract infection during pregnancy. Cochrane Database Syst. Rev. 2015, 11, CD009279. [Google Scholar] [CrossRef] [PubMed]
- Hooton, T.M. Recurrent urinary tract infection in women. Int. J. Antimicrob. Agents 2001, 17, 259–268. [Google Scholar] [CrossRef]
- Vahlensieck, W.; Bauer, H.-W.; Piechota, H.J.; Ludwig, M.; Wagenlehner, F. Prophylaxe rezidivierender Harnwegsinfektionen (Prophylaxis of recurrent urinary tract infections). Urologe A 2014, 53, 1468–1475. [Google Scholar] [CrossRef]
- Wagenlehner, F.M.E.; Vahlensieck, W.; Bauer, H.W.; Weidner, W.; Naber, K.G.; Piechota, H.J. Primär- und Sekundärprävention von Harnwegsinfektionen (Primary and secondary prevention of urinary tract infections). Urologe A 2011, 50, 1248, 1250–1252, 1254–1256. [Google Scholar] [CrossRef] [PubMed]
- Sanyaolu, L.; Best, V.; Cannings-John, R.; Wood, F.; Edwards, A.; Akbari, A.; Hayward, G.; Ahmed, H. Recurrent urinary tract infections and prophylactic antibiotic use in women: A cross-sectional study in primary care. Br. J. Gen. Pract. 2024, 74, e619–e627. [Google Scholar] [CrossRef] [PubMed]
- Schneeberger, C.; Stolk, R.P.; DeVries, J.H.; Schneeberger, P.M.; Herings, R.M.; Geerlings, S.E. Differences in the pattern of antibiotic prescription profile and recurrence rate for possible urinary tract infections in women with and without diabetes. Diabetes Care 2008, 31, 1380–1385. [Google Scholar] [CrossRef]
- Barmer-GEK-Arzneimittel-Report; Schriftenreihe zur Gesundheitsanalyse, Asgard-Verl.-Service: Siegburg, Germany, 2015; Volume 32.
- Wada, K.; Tsuboi, I.; Takahashi, S.; Yasuda, M.; Miyazaki, J.; Kobayashi, K.; Matsumoto, M.; Hayami, H.; Yamamoto, S.; Kiyota, H.; et al. Third nationwide surveillance of bacterial pathogens in patients with acute uncomplicated cystitis conducted by the Japanese surveillance committee during 2020 and 2021: Antimicrobial susceptibility of Escherichia coli, Klebsiella pneumoniae, and Staphylococcus saprophyticus. J. Infect. Chemother. 2024, 30, 277–285. [Google Scholar] [CrossRef] [PubMed]
- Kresken, M.; Pfeifer, Y.; Wagenlehner, F.; Werner, G.; Wohlfarth, E.; Study Group ‘Antimicrobial Resistance’of the Paul Ehrlich Society for Infection Therapy. Resistance to Mecillinam and Nine Other Antibiotics for Oral Use in Escherichia coli Isolated from Urine Specimens of Primary Care Patients in Germany, 2019/20. Antibiotics 2022, 11, 751. [Google Scholar] [CrossRef] [PubMed]
- Triebner, K.; Markevych, I.; Hustad, S.; Benediktsdóttir, B.; Forsberg, B.; Franklin, K.A.; Blanco, J.A.G.; Holm, M.; Jaquemin, B.; Jarvis, D.; et al. Residential surrounding greenspace and age at menopause: A 20-year European study (ECRHS). Environ. Int. 2019, 132, 105088. [Google Scholar] [CrossRef]
- Adamopoulos, D.A.; Karamertzanis, M.; Thomopoulos, A.; Pappa, A.; Koukkou, E.; Nicopoulou, S.C. Age at menopause and prevalence of its different types in contemporary Greek women. Menopause 2002, 9, 443–448. [Google Scholar] [CrossRef]
- Parazzini, F. Determinants of age at menopause in women attending menopause clinics in Italy. Maturitas 2007, 56, 280–287. [Google Scholar] [CrossRef]
- Beyaert, I. Mikrobiologie in der Urologischen Praxis: 9. Überarbeitete Auflage, 9. Auflage; WordPress: Berlin, Germany, 2023. [Google Scholar]
- Schmiemann, G.; Eva, K.G. Brennen Beim Wasserlassen: S3-Leitlinie und Anwenderversion der S3-Leitlinie Harnwegsinfektionen; DEGAM-Leitlinie, Nr. 1. Omikron Publ: Düsseldorf, Germany, 2018. [Google Scholar]
Bacterium | n | % |
---|---|---|
E. coli | 48 | 57 |
S. aureus | 6 | 7.1 |
enterococci | 6 | 7.1 |
Proteus spp. | 5 | 6 |
Strept. agalactiae | 5 | 6 |
Enterobacter cloacae | 3 | 3.6 |
Klebsiella oxytoca | 3 | 3.6 |
Pseudomonas aeruginosa | 3 | 3.6 |
Klebsiella pneumoniae | 2 | 2.4 |
Citrobacter species | 1 | 1.2 |
Serratia marcescens | 1 | 1.2 |
Antibiotics | Tested n (All) | Resistance % (All) | Tested n (Pre-Menopausal) | Resistance % (Pre-Menopausal) | Tested n (Post-Menopausal) | Resistance % (Post-Menopausal) |
---|---|---|---|---|---|---|
Ciprofloxacin | 74 | 18.9 | 16 | 18.8 | 58 | 19 |
Trimethoprime-sulfamethoxazole | 82 | 29.3 | 19 | 26.3 | 63 | 30.2 |
Nitrofurantoin | 81 | 17.3 | 18 | 11.1 | 63 | 19 |
Nitroxoline | 71 | 12.7 | 16 | 6.3 | 55 | 14.5 |
Antibiotics | Tested n (All) | Resistance % (All) | Tested n (Pre-Menopausal) | Resistance % (Pre-Menopausal) | Tested n (Post-Menopausal) | Resistance % (Post-Menopausal) |
---|---|---|---|---|---|---|
Ciprofloxacin | 45 | 17.8 | 11 | 27.3 | 34 | 14.7 |
Trimethoprime-sulfamethoxazole | 48 | 25 | 12 | 25 | 36 | 25 |
Nitrofurantoin | 48 | 4.2 | 12 | 0 | 36 | 5.6 |
Nitroxoline | 47 | 0 | 11 | 0 | 36 | 0 |
Bacterium | n | % |
---|---|---|
Escherichia coli | 12 | 60 |
Proteus spp. | 2 | 10 |
Strept. agalactiae | 2 | 10 |
S. aureus | 1 | 5 |
Klebsiella oxytoca | 1 | 5 |
Serratia marcescens | 1 | 5 |
enterococci | 1 | 5 |
Bacterium | n | % |
---|---|---|
Escherichia coli | 36 | 57.1 |
Staphylococcus aureus | 5 | 7.9 |
enterococci | 5 | 7.9 |
Enterobacter cloacae | 3 | 4.8 |
Proteus spp. | 3 | 4.8 |
Streptococcus agalacticae | 3 | 4.8 |
Pseudomonas aeruginosa | 3 | 4.8 |
Klebsiella pneumoniae | 2 | 3.2 |
Klebsiella oxytoca | 2 | 3.2 |
Citrobacter species | 1 | 1.6 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Spachmann, P.J.; Radlmaier, M.; Denzinger, S.; Burger, M.; Breyer, J.; Otto, W.; Schnabel, M.J.; Vergho, D. Recurrent Cystitis in Women—A Real-World Analysis of Bacteria Spectrum and Resistance Situation for Calculated Therapy. Antibiotics 2024, 13, 890. https://doi.org/10.3390/antibiotics13090890
Spachmann PJ, Radlmaier M, Denzinger S, Burger M, Breyer J, Otto W, Schnabel MJ, Vergho D. Recurrent Cystitis in Women—A Real-World Analysis of Bacteria Spectrum and Resistance Situation for Calculated Therapy. Antibiotics. 2024; 13(9):890. https://doi.org/10.3390/antibiotics13090890
Chicago/Turabian StyleSpachmann, Philipp J., Maximilian Radlmaier, Stefan Denzinger, Maximilian Burger, Johannes Breyer, Wolfgang Otto, Marco J. Schnabel, and Daniel Vergho. 2024. "Recurrent Cystitis in Women—A Real-World Analysis of Bacteria Spectrum and Resistance Situation for Calculated Therapy" Antibiotics 13, no. 9: 890. https://doi.org/10.3390/antibiotics13090890
APA StyleSpachmann, P. J., Radlmaier, M., Denzinger, S., Burger, M., Breyer, J., Otto, W., Schnabel, M. J., & Vergho, D. (2024). Recurrent Cystitis in Women—A Real-World Analysis of Bacteria Spectrum and Resistance Situation for Calculated Therapy. Antibiotics, 13(9), 890. https://doi.org/10.3390/antibiotics13090890